nodes	percent_of_prediction	percent_of_DWPC	metapath
Nebivolol—Allergic cutaneous angiitis—Methotrexate—testicular cancer	0.0217	0.0217	CcSEcCtD
Nebivolol—Renal failure acute—Chlorambucil—testicular cancer	0.0173	0.0173	CcSEcCtD
Nebivolol—Leukocytoclastic vasculitis—Methotrexate—testicular cancer	0.0141	0.0141	CcSEcCtD
Nebivolol—Renal failure acute—Ifosfamide—testicular cancer	0.0115	0.0115	CcSEcCtD
Nebivolol—Acute coronary syndrome—Vinblastine—testicular cancer	0.0111	0.0111	CcSEcCtD
Nebivolol—Myocardial infarction—Vinblastine—testicular cancer	0.0111	0.0111	CcSEcCtD
Nebivolol—Psoriasis—Methotrexate—testicular cancer	0.011	0.011	CcSEcCtD
Nebivolol—Bronchospasm—Bleomycin—testicular cancer	0.0105	0.0105	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Dactinomycin—testicular cancer	0.0104	0.0104	CcSEcCtD
Nebivolol—Psoriasis—Epirubicin—testicular cancer	0.0103	0.0103	CcSEcCtD
Nebivolol—Renal failure acute—Cisplatin—testicular cancer	0.00989	0.00989	CcSEcCtD
Nebivolol—Psoriasis—Doxorubicin—testicular cancer	0.00951	0.00951	CcSEcCtD
Nebivolol—Acute coronary syndrome—Bleomycin—testicular cancer	0.00942	0.00942	CcSEcCtD
Nebivolol—Myocardial infarction—Bleomycin—testicular cancer	0.00936	0.00936	CcSEcCtD
Nebivolol—Bronchospasm—Ifosfamide—testicular cancer	0.009	0.009	CcSEcCtD
Nebivolol—Angioedema—Chlorambucil—testicular cancer	0.00881	0.00881	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Cisplatin—testicular cancer	0.00822	0.00822	CcSEcCtD
Nebivolol—Acute coronary syndrome—Ifosfamide—testicular cancer	0.00805	0.00805	CcSEcCtD
Nebivolol—Myocardial infarction—Ifosfamide—testicular cancer	0.008	0.008	CcSEcCtD
Nebivolol—Vertigo—Vinblastine—testicular cancer	0.00794	0.00794	CcSEcCtD
Nebivolol—Thrombocytopenia—Chlorambucil—testicular cancer	0.00771	0.00771	CcSEcCtD
Nebivolol—Bradycardia—Ifosfamide—testicular cancer	0.00746	0.00746	CcSEcCtD
Nebivolol—Bronchospasm—Etoposide—testicular cancer	0.00711	0.00711	CcSEcCtD
Nebivolol—Thrombocytopenia—Vinblastine—testicular cancer	0.00706	0.00706	CcSEcCtD
Nebivolol—Acute coronary syndrome—Cisplatin—testicular cancer	0.00694	0.00694	CcSEcCtD
Nebivolol—Myocardial infarction—Cisplatin—testicular cancer	0.0069	0.0069	CcSEcCtD
Nebivolol—Cardiac disorder—Ifosfamide—testicular cancer	0.0068	0.0068	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00679	0.00679	CcSEcCtD
Nebivolol—Fatigue—Chlorambucil—testicular cancer	0.00679	0.00679	CcSEcCtD
Nebivolol—Atrioventricular block—Epirubicin—testicular cancer	0.00666	0.00666	CcSEcCtD
Nebivolol—Paraesthesia—Vinblastine—testicular cancer	0.00648	0.00648	CcSEcCtD
Nebivolol—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00644	0.00644	CcSEcCtD
Nebivolol—Bradycardia—Cisplatin—testicular cancer	0.00643	0.00643	CcSEcCtD
Nebivolol—Mental disorder—Ifosfamide—testicular cancer	0.00642	0.00642	CcSEcCtD
Nebivolol—Malnutrition—Ifosfamide—testicular cancer	0.00638	0.00638	CcSEcCtD
Nebivolol—Acute coronary syndrome—Etoposide—testicular cancer	0.00636	0.00636	CcSEcCtD
Nebivolol—Chest pain—Bleomycin—testicular cancer	0.00635	0.00635	CcSEcCtD
Nebivolol—Myocardial infarction—Etoposide—testicular cancer	0.00632	0.00632	CcSEcCtD
Nebivolol—Urticaria—Chlorambucil—testicular cancer	0.00625	0.00625	CcSEcCtD
Nebivolol—Abdominal pain—Chlorambucil—testicular cancer	0.00622	0.00622	CcSEcCtD
Nebivolol—Atrioventricular block—Doxorubicin—testicular cancer	0.00616	0.00616	CcSEcCtD
Nebivolol—Thrombocytopenia—Bleomycin—testicular cancer	0.00596	0.00596	CcSEcCtD
Nebivolol—Gastrointestinal pain—Vinblastine—testicular cancer	0.0059	0.0059	CcSEcCtD
Nebivolol—Cardiac disorder—Cisplatin—testicular cancer	0.00586	0.00586	CcSEcCtD
Nebivolol—Angioedema—Ifosfamide—testicular cancer	0.00583	0.00583	CcSEcCtD
Nebivolol—Hypersensitivity—Chlorambucil—testicular cancer	0.0058	0.0058	CcSEcCtD
Nebivolol—Vertigo—Ifosfamide—testicular cancer	0.00573	0.00573	CcSEcCtD
Nebivolol—Abdominal pain—Vinblastine—testicular cancer	0.0057	0.0057	CcSEcCtD
Nebivolol—Asthenia—Chlorambucil—testicular cancer	0.00565	0.00565	CcSEcCtD
Nebivolol—Pruritus—Chlorambucil—testicular cancer	0.00557	0.00557	CcSEcCtD
Nebivolol—Thrombocytopenia—Dactinomycin—testicular cancer	0.00556	0.00556	CcSEcCtD
Nebivolol—Malnutrition—Cisplatin—testicular cancer	0.0055	0.0055	CcSEcCtD
Nebivolol—Paraesthesia—Bleomycin—testicular cancer	0.00547	0.00547	CcSEcCtD
Nebivolol—Dyspnoea—Bleomycin—testicular cancer	0.00543	0.00543	CcSEcCtD
Nebivolol—Chest pain—Ifosfamide—testicular cancer	0.00543	0.00543	CcSEcCtD
Nebivolol—Renal failure acute—Methotrexate—testicular cancer	0.00543	0.00543	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00539	0.00539	CcSEcCtD
Nebivolol—Diarrhoea—Chlorambucil—testicular cancer	0.00538	0.00538	CcSEcCtD
Nebivolol—Cardiac disorder—Etoposide—testicular cancer	0.00537	0.00537	CcSEcCtD
Nebivolol—Hypersensitivity—Vinblastine—testicular cancer	0.00531	0.00531	CcSEcCtD
Nebivolol—Asthenia—Vinblastine—testicular cancer	0.00517	0.00517	CcSEcCtD
Nebivolol—Nervous system disorder—Ifosfamide—testicular cancer	0.00511	0.00511	CcSEcCtD
Nebivolol—Thrombocytopenia—Ifosfamide—testicular cancer	0.0051	0.0051	CcSEcCtD
Nebivolol—Renal failure acute—Epirubicin—testicular cancer	0.00508	0.00508	CcSEcCtD
Nebivolol—Skin disorder—Ifosfamide—testicular cancer	0.00506	0.00506	CcSEcCtD
Nebivolol—Vomiting—Chlorambucil—testicular cancer	0.005	0.005	CcSEcCtD
Nebivolol—Diarrhoea—Vinblastine—testicular cancer	0.00493	0.00493	CcSEcCtD
Nebivolol—Fatigue—Dactinomycin—testicular cancer	0.0049	0.0049	CcSEcCtD
Nebivolol—Urticaria—Bleomycin—testicular cancer	0.00484	0.00484	CcSEcCtD
Nebivolol—Dizziness—Vinblastine—testicular cancer	0.00477	0.00477	CcSEcCtD
Nebivolol—Renal failure acute—Doxorubicin—testicular cancer	0.0047	0.0047	CcSEcCtD
Nebivolol—Nausea—Chlorambucil—testicular cancer	0.00467	0.00467	CcSEcCtD
Nebivolol—Paraesthesia—Ifosfamide—testicular cancer	0.00467	0.00467	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00465	0.00465	CcSEcCtD
Nebivolol—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00465	0.00465	CcSEcCtD
Nebivolol—Dyspnoea—Ifosfamide—testicular cancer	0.00464	0.00464	CcSEcCtD
Nebivolol—Somnolence—Ifosfamide—testicular cancer	0.00463	0.00463	CcSEcCtD
Nebivolol—Vomiting—Vinblastine—testicular cancer	0.00459	0.00459	CcSEcCtD
Nebivolol—Vertigo—Etoposide—testicular cancer	0.00453	0.00453	CcSEcCtD
Nebivolol—Headache—Vinblastine—testicular cancer	0.00452	0.00452	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00449	0.00449	CcSEcCtD
Nebivolol—Abdominal pain—Dactinomycin—testicular cancer	0.00449	0.00449	CcSEcCtD
Nebivolol—Fatigue—Ifosfamide—testicular cancer	0.00449	0.00449	CcSEcCtD
Nebivolol—Hypersensitivity—Bleomycin—testicular cancer	0.00449	0.00449	CcSEcCtD
Nebivolol—Loss of consciousness—Etoposide—testicular cancer	0.00443	0.00443	CcSEcCtD
Nebivolol—Nervous system disorder—Cisplatin—testicular cancer	0.0044	0.0044	CcSEcCtD
Nebivolol—Thrombocytopenia—Cisplatin—testicular cancer	0.00439	0.00439	CcSEcCtD
Nebivolol—Asthenia—Bleomycin—testicular cancer	0.00437	0.00437	CcSEcCtD
Nebivolol—Skin disorder—Cisplatin—testicular cancer	0.00436	0.00436	CcSEcCtD
Nebivolol—Pruritus—Bleomycin—testicular cancer	0.00431	0.00431	CcSEcCtD
Nebivolol—Chest pain—Etoposide—testicular cancer	0.00429	0.00429	CcSEcCtD
Nebivolol—Nausea—Vinblastine—testicular cancer	0.00428	0.00428	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00426	0.00426	CcSEcCtD
Nebivolol—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00426	0.00426	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Epirubicin—testicular cancer	0.00422	0.00422	CcSEcCtD
Nebivolol—Hypersensitivity—Dactinomycin—testicular cancer	0.00419	0.00419	CcSEcCtD
Nebivolol—Urticaria—Ifosfamide—testicular cancer	0.00414	0.00414	CcSEcCtD
Nebivolol—Abdominal pain—Ifosfamide—testicular cancer	0.00412	0.00412	CcSEcCtD
Nebivolol—Asthenia—Dactinomycin—testicular cancer	0.00408	0.00408	CcSEcCtD
Nebivolol—Paraesthesia—Cisplatin—testicular cancer	0.00403	0.00403	CcSEcCtD
Nebivolol—Thrombocytopenia—Etoposide—testicular cancer	0.00403	0.00403	CcSEcCtD
Nebivolol—Dyspnoea—Cisplatin—testicular cancer	0.004	0.004	CcSEcCtD
Nebivolol—Skin disorder—Etoposide—testicular cancer	0.00399	0.00399	CcSEcCtD
Nebivolol—Erectile dysfunction—Methotrexate—testicular cancer	0.00399	0.00399	CcSEcCtD
Nebivolol—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.00391	0.00391	CcSEcCtD
Nebivolol—Diarrhoea—Dactinomycin—testicular cancer	0.00389	0.00389	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00387	0.00387	CcSEcCtD
Nebivolol—Vomiting—Bleomycin—testicular cancer	0.00387	0.00387	CcSEcCtD
Nebivolol—Rash—Bleomycin—testicular cancer	0.00384	0.00384	CcSEcCtD
Nebivolol—Dermatitis—Bleomycin—testicular cancer	0.00384	0.00384	CcSEcCtD
Nebivolol—Hypersensitivity—Ifosfamide—testicular cancer	0.00384	0.00384	CcSEcCtD
Nebivolol—Asthenia—Ifosfamide—testicular cancer	0.00374	0.00374	CcSEcCtD
Nebivolol—Paraesthesia—Etoposide—testicular cancer	0.00369	0.00369	CcSEcCtD
Nebivolol—Pruritus—Ifosfamide—testicular cancer	0.00368	0.00368	CcSEcCtD
Nebivolol—Dyspnoea—Etoposide—testicular cancer	0.00367	0.00367	CcSEcCtD
Nebivolol—Somnolence—Etoposide—testicular cancer	0.00366	0.00366	CcSEcCtD
Nebivolol—Nausea—Bleomycin—testicular cancer	0.00362	0.00362	CcSEcCtD
Nebivolol—Vomiting—Dactinomycin—testicular cancer	0.00361	0.00361	CcSEcCtD
Nebivolol—Rash—Dactinomycin—testicular cancer	0.00358	0.00358	CcSEcCtD
Nebivolol—Diarrhoea—Ifosfamide—testicular cancer	0.00356	0.00356	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Etoposide—testicular cancer	0.00355	0.00355	CcSEcCtD
Nebivolol—Fatigue—Etoposide—testicular cancer	0.00354	0.00354	CcSEcCtD
Nebivolol—Dizziness—Ifosfamide—testicular cancer	0.00344	0.00344	CcSEcCtD
Nebivolol—Nausea—Dactinomycin—testicular cancer	0.00337	0.00337	CcSEcCtD
Nebivolol—Gastrointestinal pain—Etoposide—testicular cancer	0.00336	0.00336	CcSEcCtD
Nebivolol—Vomiting—Ifosfamide—testicular cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Hypersensitivity—Cisplatin—testicular cancer	0.00331	0.00331	CcSEcCtD
Nebivolol—Bradycardia—Epirubicin—testicular cancer	0.0033	0.0033	CcSEcCtD
Nebivolol—Rash—Ifosfamide—testicular cancer	0.00328	0.00328	CcSEcCtD
Nebivolol—Dermatitis—Ifosfamide—testicular cancer	0.00328	0.00328	CcSEcCtD
Nebivolol—Urticaria—Etoposide—testicular cancer	0.00327	0.00327	CcSEcCtD
Nebivolol—Abdominal pain—Etoposide—testicular cancer	0.00325	0.00325	CcSEcCtD
Nebivolol—Asthenia—Cisplatin—testicular cancer	0.00322	0.00322	CcSEcCtD
Nebivolol—Cardiac disorder—Methotrexate—testicular cancer	0.00322	0.00322	CcSEcCtD
Nebivolol—Oedema peripheral—Epirubicin—testicular cancer	0.0032	0.0032	CcSEcCtD
Nebivolol—Nausea—Ifosfamide—testicular cancer	0.00309	0.00309	CcSEcCtD
Nebivolol—Diarrhoea—Cisplatin—testicular cancer	0.00307	0.00307	CcSEcCtD
Nebivolol—Bradycardia—Doxorubicin—testicular cancer	0.00306	0.00306	CcSEcCtD
Nebivolol—Mental disorder—Methotrexate—testicular cancer	0.00304	0.00304	CcSEcCtD
Nebivolol—Hypersensitivity—Etoposide—testicular cancer	0.00303	0.00303	CcSEcCtD
Nebivolol—Malnutrition—Methotrexate—testicular cancer	0.00302	0.00302	CcSEcCtD
Nebivolol—Cardiac disorder—Epirubicin—testicular cancer	0.00301	0.00301	CcSEcCtD
Nebivolol—Oedema peripheral—Doxorubicin—testicular cancer	0.00296	0.00296	CcSEcCtD
Nebivolol—Asthenia—Etoposide—testicular cancer	0.00295	0.00295	CcSEcCtD
Nebivolol—Pruritus—Etoposide—testicular cancer	0.00291	0.00291	CcSEcCtD
Nebivolol—Vomiting—Cisplatin—testicular cancer	0.00285	0.00285	CcSEcCtD
Nebivolol—Mental disorder—Epirubicin—testicular cancer	0.00284	0.00284	CcSEcCtD
Nebivolol—Rash—Cisplatin—testicular cancer	0.00283	0.00283	CcSEcCtD
Nebivolol—Dermatitis—Cisplatin—testicular cancer	0.00283	0.00283	CcSEcCtD
Nebivolol—Malnutrition—Epirubicin—testicular cancer	0.00282	0.00282	CcSEcCtD
Nebivolol—Diarrhoea—Etoposide—testicular cancer	0.00281	0.00281	CcSEcCtD
Nebivolol—Cardiac disorder—Doxorubicin—testicular cancer	0.00279	0.00279	CcSEcCtD
Nebivolol—Dizziness—Etoposide—testicular cancer	0.00272	0.00272	CcSEcCtD
Nebivolol—Vertigo—Methotrexate—testicular cancer	0.00271	0.00271	CcSEcCtD
Nebivolol—Nausea—Cisplatin—testicular cancer	0.00267	0.00267	CcSEcCtD
Nebivolol—Mental disorder—Doxorubicin—testicular cancer	0.00263	0.00263	CcSEcCtD
Nebivolol—Vomiting—Etoposide—testicular cancer	0.00261	0.00261	CcSEcCtD
Nebivolol—Malnutrition—Doxorubicin—testicular cancer	0.00261	0.00261	CcSEcCtD
Nebivolol—Rash—Etoposide—testicular cancer	0.00259	0.00259	CcSEcCtD
Nebivolol—Dermatitis—Etoposide—testicular cancer	0.00259	0.00259	CcSEcCtD
Nebivolol—Headache—Etoposide—testicular cancer	0.00258	0.00258	CcSEcCtD
Nebivolol—Chest pain—Methotrexate—testicular cancer	0.00257	0.00257	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00255	0.00255	CcSEcCtD
Nebivolol—Vertigo—Epirubicin—testicular cancer	0.00254	0.00254	CcSEcCtD
Nebivolol—Syncope—Epirubicin—testicular cancer	0.00253	0.00253	CcSEcCtD
Nebivolol—Loss of consciousness—Epirubicin—testicular cancer	0.00248	0.00248	CcSEcCtD
Nebivolol—Nausea—Etoposide—testicular cancer	0.00244	0.00244	CcSEcCtD
Nebivolol—Nervous system disorder—Methotrexate—testicular cancer	0.00242	0.00242	CcSEcCtD
Nebivolol—Thrombocytopenia—Methotrexate—testicular cancer	0.00241	0.00241	CcSEcCtD
Nebivolol—Chest pain—Epirubicin—testicular cancer	0.0024	0.0024	CcSEcCtD
Nebivolol—Skin disorder—Methotrexate—testicular cancer	0.00239	0.00239	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00239	0.00239	CcSEcCtD
Nebivolol—Vertigo—Doxorubicin—testicular cancer	0.00235	0.00235	CcSEcCtD
Nebivolol—Syncope—Doxorubicin—testicular cancer	0.00234	0.00234	CcSEcCtD
Nebivolol—Loss of consciousness—Doxorubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Nebivolol—Shock—Epirubicin—testicular cancer	0.00227	0.00227	CcSEcCtD
Nebivolol—Nervous system disorder—Epirubicin—testicular cancer	0.00226	0.00226	CcSEcCtD
Nebivolol—Thrombocytopenia—Epirubicin—testicular cancer	0.00226	0.00226	CcSEcCtD
Nebivolol—Skin disorder—Epirubicin—testicular cancer	0.00224	0.00224	CcSEcCtD
Nebivolol—Insomnia—Methotrexate—testicular cancer	0.00223	0.00223	CcSEcCtD
Nebivolol—Chest pain—Doxorubicin—testicular cancer	0.00222	0.00222	CcSEcCtD
Nebivolol—Paraesthesia—Methotrexate—testicular cancer	0.00221	0.00221	CcSEcCtD
Nebivolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Nebivolol—Dyspnoea—Methotrexate—testicular cancer	0.0022	0.0022	CcSEcCtD
Nebivolol—Somnolence—Methotrexate—testicular cancer	0.00219	0.00219	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00213	0.00213	CcSEcCtD
Nebivolol—Fatigue—Methotrexate—testicular cancer	0.00212	0.00212	CcSEcCtD
Nebivolol—Shock—Doxorubicin—testicular cancer	0.0021	0.0021	CcSEcCtD
Nebivolol—Nervous system disorder—Doxorubicin—testicular cancer	0.00209	0.00209	CcSEcCtD
Nebivolol—Thrombocytopenia—Doxorubicin—testicular cancer	0.00209	0.00209	CcSEcCtD
Nebivolol—Insomnia—Epirubicin—testicular cancer	0.00208	0.00208	CcSEcCtD
Nebivolol—Skin disorder—Doxorubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Nebivolol—Paraesthesia—Epirubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Nebivolol—Dyspnoea—Epirubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Nebivolol—Somnolence—Epirubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Nebivolol—Gastrointestinal pain—Methotrexate—testicular cancer	0.00201	0.00201	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Nebivolol—Fatigue—Epirubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Nebivolol—Urticaria—Methotrexate—testicular cancer	0.00196	0.00196	CcSEcCtD
Nebivolol—Abdominal pain—Methotrexate—testicular cancer	0.00195	0.00195	CcSEcCtD
Nebivolol—Insomnia—Doxorubicin—testicular cancer	0.00193	0.00193	CcSEcCtD
Nebivolol—Paraesthesia—Doxorubicin—testicular cancer	0.00191	0.00191	CcSEcCtD
Nebivolol—Dyspnoea—Doxorubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Nebivolol—Somnolence—Doxorubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Nebivolol—Gastrointestinal pain—Epirubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Nebivolol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Nebivolol—Fatigue—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Nebivolol—Urticaria—Epirubicin—testicular cancer	0.00183	0.00183	CcSEcCtD
Nebivolol—Abdominal pain—Epirubicin—testicular cancer	0.00182	0.00182	CcSEcCtD
Nebivolol—Hypersensitivity—Methotrexate—testicular cancer	0.00181	0.00181	CcSEcCtD
Nebivolol—Asthenia—Methotrexate—testicular cancer	0.00177	0.00177	CcSEcCtD
Nebivolol—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Nebivolol—Pruritus—Methotrexate—testicular cancer	0.00174	0.00174	CcSEcCtD
Nebivolol—Hypersensitivity—Epirubicin—testicular cancer	0.0017	0.0017	CcSEcCtD
Nebivolol—Urticaria—Doxorubicin—testicular cancer	0.00169	0.00169	CcSEcCtD
Nebivolol—Abdominal pain—Doxorubicin—testicular cancer	0.00169	0.00169	CcSEcCtD
Nebivolol—Diarrhoea—Methotrexate—testicular cancer	0.00169	0.00169	CcSEcCtD
Nebivolol—Asthenia—Epirubicin—testicular cancer	0.00165	0.00165	CcSEcCtD
Nebivolol—Pruritus—Epirubicin—testicular cancer	0.00163	0.00163	CcSEcCtD
Nebivolol—Dizziness—Methotrexate—testicular cancer	0.00163	0.00163	CcSEcCtD
Nebivolol—Diarrhoea—Epirubicin—testicular cancer	0.00158	0.00158	CcSEcCtD
Nebivolol—Hypersensitivity—Doxorubicin—testicular cancer	0.00157	0.00157	CcSEcCtD
Nebivolol—Vomiting—Methotrexate—testicular cancer	0.00157	0.00157	CcSEcCtD
Nebivolol—Rash—Methotrexate—testicular cancer	0.00155	0.00155	CcSEcCtD
Nebivolol—Dermatitis—Methotrexate—testicular cancer	0.00155	0.00155	CcSEcCtD
Nebivolol—Headache—Methotrexate—testicular cancer	0.00154	0.00154	CcSEcCtD
Nebivolol—Asthenia—Doxorubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Nebivolol—Dizziness—Epirubicin—testicular cancer	0.00152	0.00152	CcSEcCtD
Nebivolol—Pruritus—Doxorubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Nebivolol—Vomiting—Epirubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Nebivolol—Nausea—Methotrexate—testicular cancer	0.00146	0.00146	CcSEcCtD
Nebivolol—Diarrhoea—Doxorubicin—testicular cancer	0.00146	0.00146	CcSEcCtD
Nebivolol—Rash—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Nebivolol—Dermatitis—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Nebivolol—Headache—Epirubicin—testicular cancer	0.00144	0.00144	CcSEcCtD
Nebivolol—Dizziness—Doxorubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Nebivolol—Nausea—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Nebivolol—Vomiting—Doxorubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Nebivolol—Rash—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Nebivolol—Dermatitis—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Nebivolol—Headache—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Nebivolol—Nausea—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
